ClinicalTrials.gg
CompletedNCT05830071Updated Sep 4, 2024

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

A Phase 1 interventional study of CHF5993 and CHF5259 in Asthma and Chronic Obstructive Pulmonary Disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing glycopyrrolate in Asthma — 1 open to participants now, 1 under way, none of them phase 3. Glycopyrrolate · Asthma.

Enrollment
5th of 10
95 · median 69
Started
2023
the only one that year
Phase 1
2 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
3 of 10
Chiesi Farmaceutici S.p.A.

Among the 10 studies testing glycopyrrolate in Asthma, this one is the 5th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 1, and was the 10th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 10 studies testing glycopyrrolate in Asthma is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing glycopyrrolate in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the potential for cardiac repolarization, according to electrocardiographic monitoring (including QT and QTc intervals), of two dose levels of CHF5993 pMDI (beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB)) and of one dose of CHF5259 (GB) in healthy subjects compared to moxifloxacin and placebo.

Read the detailed description

The main purpose of this study is to evaluate the effect of a single supratherapeutic dose of inhaled BDP/FF/GB on cardiovascular safety. The secondary purposes of the study are to: 1) evaluate the effect of a single supratherapeutic dose of inhaled BDP/FF/GB and GB on cardiovascular safety; 2) establish assay sensitivity by demonstrating the effect of a single oral dose of 400 mg moxifloxacin on cardiovascular safety; 3) determine the pharmacokinetics (PK) of single, inhaled therapeutic and supratherapeutic BDP/FF/GB doses and supratherapeutic GB dose; 4) determine if there is a relationship between the duration of the QTc intervals and the plasma concentrations of the B17MP (beclomethasone 17monopropionate active metabolite of BDP), FF and GB following the administration of BDP/FF/GB and GB pMDIs; 5) generate additional safety and tolerability information.

03

Conditions studied

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Subject's written ;
  • 18-55 years of age;
  • Ability to understand the study procedures, the risks involved and ability to be trained to use the inhalers correctly;
  • (BMI) between 18 and 32 kg/m2 extremes inclusive;
  • Non- or ex-smokers who smoked \< 5 pack years and stopped smoking > 1 year prior to screening;
  • Good physical and mental status, determined on the basis of the medical history and a general clinical examination;
  • Vital signs within normal limits at screening and prior to randomization: Diastolic BP 40-89 mmHg, Systolic BP 90-139 mmHg extremes included (mean value of three measures). Body temperature \< 37.5°C;
  • 12 -lead digitized (12-lead ECG) in triplicate considered as normal (40 ≤ Heart rate ≤ 110bpm, 120 ms ≤ PR ≤ 220 ms, QRS ≤ 110 ms, ≤ 450 ms);
  • Lung function measurements within normal limits (normal values: forced expiratory volume in the 1st second []/forced vital capacity [FVC] > 0.70 and FEV1 > 80% predicted);
  • Female subjects of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable methods.

Key Exclusion Criteria:

  • Participation in another clinical trial where drug was received and last investigations within the last 8 weeks;
  • abnormal standard ECG at screening;
  • Clinically relevant and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorders that may interfere with successful completion of this protocol;
  • Subjects with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic;
  • Subjects with history of breathing problems (i.e., history of asthma including childhood asthma);
  • Positive urine test for cotinine;
  • Intake of non-permitted concomitant medications in the predefined period prior to screening or prior to randomization, or the subject is expected to take non-permitted concomitant medications during the study;
  • Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or to randomization;
  • Known intolerance and/or to any of the contained in the formulation used in the trial;
  • Women who are pregnant or lactating;
  • Use of any kind of smoking electronic devices within 6 months before Screening.

Other inclusion/exclusion criteria as defined by the protocol.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Single therapeutic dose of CHF5993 (BDP/FF/GB)

    Dose: BDP/FF/GB 100/6/12.5 μg, single dose inhalation via pressurized metered dose inhaler (2 puffs from 1 BDP/FF/GB 100/6/12.5 μg pMDI + 2 puffs from 3 placebo pMDI)

    Drug: CHF5993 · Drug: CHF5993 Placebo

  • Experimental
    Single supra-therapeutic dose of CHF5993 (BDP/FF/GB)

    Dose: BDP/FF/GB 800/48/100 μg single dose inhalation, via pressurized metered dose inhaler (8 puffs from 4 BDP/FF/GB 100/6/12.5 μg pMDI)

    Drug: CHF5993

  • Experimental
    Single supra-therapeutic dose CHF5259 (GB)

    Dose: GB 100 μg single dose inhalation, via pressurized metered dose inhaler (8 puffs from 4 GB 12.5 μg pMDI)

    Drug: CHF5259

  • Placebo comparator
    Single dose Placebo

    Dose: placebo single dose inhalation, via pressurized metered dose inhaler 8 puffs from 4 CHF5993 placebo pMDI

    Drug: CHF5993 Placebo

  • Active comparator
    Moxifloxacin

    Dose: moxifloxacin 400 mg single dose, for oral use - open label treatment (1 tablet of moxifloxacin 400 mg PO)

    Drug: Moxifloxacin 400mg

Interventions

  • BDP/FF/GB 100/6/12.5 μg pMDI

    Also known as: beclometasone dipropionate /formoterol fumarate/glycopyrronium bromide, BDP/FF/GB

  • GB 12.5 μg pMDI

    Also known as: glycopyrronium bromide, GB

  • 400 mg Oral Tablets

    Also known as: Moxifloxacin hydrochloride

  • DrugCHF5993 Placebo

    placebo pMDI

    Also known as: BDP/FF/GB Placebo

06

What researchers measure

Primary outcomes

  1. Effect of BDP/FF/GB pMDI at therapeutic dose on the heart rate-corrected QT interval based on the Fridericia's correction (QTcF).

    Placebo-adjusted change in QTc interval based on the Fridericia's correction (ΔΔQTcF) after dosing CHF5993 pMDI (200/12/25 μg). Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 24 hours

Secondary outcomes

  1. Effect of BDP/FF/GB pMDI and GB pMDI at supra-therapeutic dose on the heart rate-corrected QT interval based on the Fridericia's correction (QTcF).

    Placebo-adjusted change from baseline in QTc interval based on the Fridericia's correction (ΔΔQTcF) after dosing CHF5993 pMDI (800/48/100 μg) and GB pMDI (100 μg). Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 24 hours

  2. Assay sensitivity by demonstrating the effect of a single oral therapeutic dose of moxifloxacin on QTcF.

    Placebo-adjusted change from baseline in QTc interval based on the Fridericia's correction (ΔΔQTcF) after dosing 400 mg of moxifloxacin. Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG

    Time frame: time 0 (pre-dose) to 6 hours

  3. Effect of BDP/FF/GB pMDI at therapeutic and supra-therapeutic dose and of GB pMDI at supra-therapeutic dose on Hearth Rate (HR).

    Placebo-adjusted change from baseline of HR (ΔΔHR) after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg) will be summarized by means of descriptive statistics at each analysis time point and by treatment. Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 24 hours

  4. Effect of BDP/FF/GB pMDI at therapeutic and supra-therapeutic dose and of GB pMDI at supra-therapeutic dose on PR interval (PR).

    Placebo-adjusted change from baseline of PR (ΔΔPR) after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg) will be summarized by means of descriptive statistics at each analysis time point and by treatment. Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 24 hours

  5. Effect of BDP/FF/GB pMDI at therapeutic and supra-therapeutic dose and of GB pMDI at supra-therapeutic dose on QRS interval (QRS).

    Placebo-adjusted change from baseline of QRS (ΔΔQRS) after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg) will be summarized by means of descriptive statistics at each analysis time point and by treatment. Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 24 hours

  6. Effect of BDP/FF/GB pMDI at therapeutic and supra-therapeutic dose and of GB pMDI at supra-therapeutic dose on individual-corrected QT interval (QTcI)

    Placebo-adjusted change from baseline in individual-corrected QT interval (ΔΔQTcI) after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg). Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 24 hours

  7. Effect of moxifloxacin at therapeutic dose on individual-corrected QT interval.

    Placebo-adjusted change from baseline in individual-corrected QT interval (ΔΔQTcI) after dosing 400 mg of moxifloxacin. Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 6 hours

  8. Changes in T-wave morphology and U-wave presence.

    Frequency of treatment-emergent changes in T-wave morphology and U-wave presence after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg). Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 24 hours

  9. Analysis of categorical outliers of Hearth Rate (HR), PR interval (PR), QRS interval (QRS) and QTcF interval (QTcF), after BDP/FF/GB pMDI dosing at therapeutic and supra-therapeutic dose, and after GB dosing at supra-therapeutic dose.

    Results of categorical outliers will be summarized by treatment in frequency tables reporting: counts and percentages for number of subjects and number of time points with 1) abnormal actual QTcF values, and 2) abnormal change from baseline of HR, PR, QRS and QTcF. Through digitised 12-lead ECG, extracted from 12-Lead Holter ECG.

    Time frame: time 0 (pre-dose) to 24 hours

  10. Analysis of Maximum plasma concentration (Cmax), pharmacokinetic parameter of FF, GB, BDP and B17MP

    Analysis of Cmax after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg).

    Time frame: time 0 (pre-dose) to 24 hours

  11. Analysis of Area under the curve from 0 to 12 hours post-dose (AUC0-12), pharmacokinetic parameter of FF, GB, BDP and B17MP

    Analysis of AUC0-12, after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg).

    Time frame: time 0 (pre-dose) to 24 hours

  12. Analysis of Area under the plasma concentration-time curve from time 0 to time t (AUC0 t), pharmacokinetic parameter of FF, GB, BDP and B17MP

    Analysis of AUC0-t after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg).

    Time frame: time 0 (pre-dose) to 24 hours

  13. Analysis of Area under the curve from time 0 to infinity (AUC0-∞), pharmacokinetic parameter of FF, GB, BDP and B17MP

    Analysis of AUC0-∞ after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg).

    Time frame: time 0 (pre-dose) to 24 hours

  14. Analysis of Time to maximum plasma concentration (tmax), pharmacokinetic parameter of FF, GB, BDP and B17MP

    Analysis of tmax, after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg).

    Time frame: time 0 (pre-dose) to 24 hours

  15. Analysis of Terminal half-life (t1/2), pharmacokinetic parameter of FF, GB, BDP and B17MP

    Analysis of t1/2, after dosing BDP/FF/GB pMDI (200/12/25 μg and 800/48/100 μg) and GB pMDI (100 μg).

    Time frame: time 0 (pre-dose) to 24 hours

  16. Incidence of Adverse events

    Number and percentage of subjects with at least one event and number of treatment emergent events

    Time frame: from study start through study completion, an average of 4 months

  17. Incidence of Adverse Drug Reactions

    Number and percentage of subjects with at least one event and number of treatment emergent events

    Time frame: from study start through study completion, an average of 4 months

  18. Change of systolic and diastolic blood pressure

    Number and percentage of subjects with with abnormal changes from baseline

    Time frame: from study start through study completion, an average of 4 months

  19. Body temperature abnormal values

    Number and percentage of subjects with at least one event and number of treatment emergent events

    Time frame: from study start through study completion, an average of 4 months

  20. Abnormal results of physical examinations

    Number and percentage of subjects with at least one event and number of treatment emergent events

    Time frame: from study start through study completion, an average of 4 months

  21. Abnormal clinical chemistry and haematology laboratory tests

    Number and percentage of subjects with at least one event and number of treatment emergent events

    Time frame: from study start through study completion, an average of 4 months

07

Study locations

1 site
  • PAREXEL Baltimore Early Phase Clinical Unit
    Baltimore, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Oct 2023, 6 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is close to that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2023
First posted
Apr 26, 2023
StartActual
Mar 29, 2023
Primary completionActual
Oct 13, 2023
CompletionActual
Oct 13, 2023
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05830071
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
Mar 29, 2023
Primary completion
Oct 13, 2023
Completion
Oct 13, 2023
Last update
Sep 4, 2024

Study contacts

Ronald Goldwater, MDCM/M.SC(A)
principal investigator · PAREXEL Baltimore Early Phase Clinical Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CHF5993 · Glycopyrrolate

Start the discussion